Drug Profile


Alternative Names: 1303; EMAB-6; LFB-R603; R603; TG-1101; TG-1303; TGTX-1101; Utuxin

Latest Information Update: 15 May 2017

Price : $50

At a glance

  • Originator GTC Biotherapeutics; LFB Biotechnologies
  • Developer Johns Hopkins University; LFB Biotechnologies; TG Therapeutics Inc
  • Class Antineoplastics; Monoclonal antibodies
  • Mechanism of Action CD20 antigen inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Neuromyelitis optica; Chronic lymphocytic leukaemia; MALT lymphoma; Non-Hodgkin's lymphoma; Diffuse large B cell lymphoma
  • New Molecular Entity Yes

Highest Development Phases

  • Phase III Chronic lymphocytic leukaemia
  • Phase II Diffuse large B cell lymphoma; Mantle-cell lymphoma; Multiple sclerosis
  • Phase I/II Non-Hodgkin's lymphoma
  • Phase I Neuromyelitis optica

Most Recent Events

  • 28 Apr 2017 Interim efficacy data from a phase I/II trial in Multiple sclerosis presented at the 69th American Academy of Neurology (AAN) annual meeting
  • 06 Mar 2017 Top-line efficacy data from a phase III GENUINE trial for Chronic lymphocytic leukaemia released by TG Therapeutics
  • 03 Mar 2017 Early pharmacodynamics data from a phase IIa trial in Multiple sclerosis released by TG Therapeutics
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top